David A. Siegel Ikena Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 173,200 shares of IKNA stock, worth $299,636. This represents 0.0% of its overall portfolio holdings.
Number of Shares
173,200
Previous 79,900
116.77%
Holding current value
$299,636
Previous $113,000
152.21%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IKNA
# of Institutions
73Shares Held
31.2MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$8.68 Million1.1% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$8.25 Million0.24% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$7.08 Million2.8% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$6.12 Million0.14% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.89 Million4.84% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $62.7M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...